{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T20:10:35Z","timestamp":1794427835191,"version":"4.9.1"},"reference-count":72,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.ygyno.2025.08.007","type":"journal-article","created":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T09:40:51Z","timestamp":1757756451000},"page":"193-202","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Embracing and implementing the WHO cervical cancer elimination campaign goals: A consensus statement by SGO, ACOG, ASCCP, ASTRO, and ABS on minimum quality care standards for cervical cancer patients in the U.S"],"prefix":"10.1016","volume":"200","author":[{"given":"Nancy","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna L.","family":"Beavis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilie L.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shane S.","family":"Neibart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junzo","family":"Chino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer Young","family":"Pierce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roisin E.","family":"O'Cearbhaill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Summer B.","family":"Dewdney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huma","family":"Farid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee-may","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Levi S.","family":"Downs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander B.","family":"Olawaiye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa K.L.","family":"Boitano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark H.","family":"Einstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deanna","family":"Teoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"Charles A.","family":"Leath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2025.08.007_bb0005","series-title":"Global strategy to accelerate the elimination of cervical cancer as a public health problem","author":"WorldHealthOrganization","year":"2020"},{"issue":"1","key":"10.1016\/j.ygyno.2025.08.007_bb0010","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"2","key":"10.1016\/j.ygyno.2025.08.007_bb0015","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/LGT.0000000000000525","article-title":"2019 ASCCP risk-based management consensus guidelines for abnormal cervical Cancer screening tests and cancer precursors","volume":"24","author":"Perkins","year":"2020","journal-title":"J. Low. Genit. Tract Dis."},{"issue":"14","key":"10.1016\/j.ygyno.2025.08.007_bb0020","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1056\/NEJMoa1917338","article-title":"HPV vaccination and the risk of invasive cervical cancer","volume":"383","author":"Lei","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.ygyno.2025.08.007_bb0025","article-title":"Human papillomavirus vaccine efficacy and effectiveness against cancer","volume":"9","author":"Kamolratanakul","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.ygyno.2025.08.007_bb0030","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/2046-4053-2-35","article-title":"Screening for cervical cancer: a systematic review and meta-analysis","volume":"2","author":"Peirson","year":"2013","journal-title":"Syst. Rev."},{"issue":"3","key":"10.1016\/j.ygyno.2025.08.007_bb0035","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.vaccine.2010.10.051","article-title":"Worsening disparities in HPV vaccine utilization among 19-26 year old women","volume":"29","author":"Dempsey","year":"2011","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.ygyno.2025.08.007_bb0040","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.amepre.2023.04.016","article-title":"Racial and ethnic disparities in cervical cancer screening from three U.S. healthcare settings","volume":"65","author":"Spencer","year":"2023","journal-title":"Am. J. Prev. Med."},{"issue":"8","key":"10.1016\/j.ygyno.2025.08.007_bb0045","article-title":"Cytology versus HPV testing for cervical cancer screening in the general population","volume":"8","author":"Koliopoulos","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"issue":"2","key":"10.1016\/j.ygyno.2025.08.007_bb0050","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ygyno.2020.08.006","article-title":"The effect of guideline-concordant care in mitigating insurance status disparities in cervical cancer","volume":"159","author":"Wu","year":"2020","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2025.08.007_bb0055","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.ygyno.2016.03.025","article-title":"Disparities in the management and outcome of cervical cancer in the United States according to health insurance status","volume":"141","author":"Churilla","year":"2016","journal-title":"Gynecol. Oncol."},{"issue":"4","key":"10.1016\/j.ygyno.2025.08.007_bb0060","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1002\/1097-0142(20010215)91:4<869::AID-CNCR1075>3.0.CO;2-D","article-title":"Equal care ensures equal survival for African-American women with cervical carcinoma","volume":"91","author":"Farley","year":"2001","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.ygyno.2025.08.007_bb0065","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.ygyno.2013.12.039","article-title":"Gynecologic cancer disparities: a report from the health disparities taskforce of the Society of Gynecologic Oncology","volume":"133","author":"Collins","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2025.08.007_bb0070","series-title":"CAP QCDR Measure Turn-around Time (TAT) for Standard Biopsies","author":"Pathologists","year":"2018"},{"key":"10.1016\/j.ygyno.2025.08.007_bb0075","first-page":"1","article-title":"Synoptic reporting: evidence-based review and future directions","volume":"2","author":"Renshaw","year":"2018","journal-title":"JCO Clin. Cancer Inform."},{"issue":"11","key":"10.1016\/j.ygyno.2025.08.007_bb0080","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.5858\/arpa.2010-0558-OA","article-title":"What impact has the introduction of a synoptic report for rectal cancer had on reporting outcomes for specialist gastrointestinal and nongastrointestinal pathologists?","volume":"135","author":"Messenger","year":"2011","journal-title":"Arch. Pathol. Lab Med."},{"issue":"7","key":"10.1016\/j.ygyno.2025.08.007_bb0085","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.10648","article-title":"Reevaluation of the US pathologist workforce size","volume":"3","author":"Robboy","year":"2020","journal-title":"JAMA Netw. Open"},{"issue":"12","key":"10.1016\/j.ygyno.2025.08.007_bb0090","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.6004\/jnccn.2023.0062","article-title":"NCCN guidelines(R) insights: cervical Cancer, version 1.2024","volume":"21","author":"Abu-Rustum","year":"2023","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"10.1016\/j.ygyno.2025.08.007_bb0095","series-title":"ACR Practice Parameter for Communication of Diagnostic Imaging Findings","author":"Radiology ACo","year":"2020"},{"key":"10.1016\/j.ygyno.2025.08.007_bb0100","series-title":"The Radiology Labor Shortage ACR.ORG","author":"Fleishon","year":"2022"},{"issue":"3 Pt B","key":"10.1016\/j.ygyno.2025.08.007_bb0105","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.jacr.2017.12.026","article-title":"Artificial intelligence and machine learning in radiology: opportunities, challenges, pitfalls, and criteria for success","volume":"15","author":"Thrall","year":"2018","journal-title":"J. Am. Coll. Radiol."},{"issue":"11","key":"10.1016\/j.ygyno.2025.08.007_bb0110","doi-asserted-by":"crossref","first-page":"7998","DOI":"10.1007\/s00330-022-08784-6","article-title":"Radiology artificial intelligence: a systematic review and evaluation of methods (RAISE)","volume":"32","author":"Kelly","year":"2022","journal-title":"Eur. Radiol."},{"key":"10.1016\/j.ygyno.2025.08.007_bb0115","first-page":"308","article-title":"The relevance of gynecologic oncologists to provide high-quality of care to women with gynecological cancer","volume":"5","author":"Minig","year":"2015","journal-title":"Front. Oncol."},{"issue":"6","key":"10.1016\/j.ygyno.2025.08.007_bb0120","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1111\/jog.13948","article-title":"Relation between the number of board-certified gynecologic oncologists per hospital and survival of cervical cancer","volume":"45","author":"Yagi","year":"2019","journal-title":"J. Obstet. Gynaecol. Res."},{"issue":"2","key":"10.1016\/j.ygyno.2025.08.007_bb0125","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ygyno.2021.08.013","article-title":"A look at the gynecologic oncologist workforce - are we meeting patient demand?","volume":"163","author":"Ackroyd","year":"2021","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2025.08.007_bb0130","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0213209","article-title":"Time to initial cancer treatment in the United States and association with survival over time: an observational study","volume":"14","author":"Khorana","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.ygyno.2025.08.007_bb0135","article-title":"Mortality due to cancer treatment delay: systematic review and meta-analysis","volume":"371","author":"Hanna","year":"2020","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.ygyno.2025.08.007_bb0140","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s00268-022-06883-5","article-title":"Time to treatment initiation for six cancer types: an analysis of data from a nationwide registry in Japan","volume":"47","author":"Watanabe","year":"2023","journal-title":"World J. Surg."},{"issue":"9","key":"10.1016\/j.ygyno.2025.08.007_bb0145","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0221946","article-title":"Effect of time interval from diagnosis to treatment for cervical cancer on survival: a nationwide cohort study","volume":"14","author":"Chen","year":"2019","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.ygyno.2025.08.007_bb0150","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ygyno.2017.12.010","article-title":"Delays in definitive cervical cancer treatment: an analysis of disparities and overall survival impact","volume":"149","author":"Ramey","year":"2018","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2025.08.007_bb0155","first-page":"19","article-title":"Shorter time to treatment is associated with improved survival in rural patients with breast cancer despite other adverse socioeconomic factors","volume":"37","author":"Nguyen","year":"2023","journal-title":"Oncology (Williston Park)"},{"issue":"2","key":"10.1016\/j.ygyno.2025.08.007_bb0160","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.ygyno.2016.11.037","article-title":"Association between timing of cervical excision procedure to minimally invasive hysterectomy and surgical complications","volume":"144","author":"Sullivan","year":"2017","journal-title":"Gynecol. Oncol."},{"issue":"10","key":"10.1016\/j.ygyno.2025.08.007_bb0165","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1136\/ijgc-2021-002921","article-title":"ConCerv: a prospective trial of conservative surgery for low-risk early-stage cervical cancer","volume":"31","author":"Schmeler","year":"2021","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"4","key":"10.1016\/j.ygyno.2025.08.007_bb0170","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1136\/ijgc-2022-004092","article-title":"Proof-of-concept randomized phase II non-inferiority trial of simple versus type B2 hysterectomy in early-stage cervical cancer <\/=2 cm (LESSER)","volume":"33","author":"Carneiro","year":"2023","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"9","key":"10.1016\/j.ygyno.2025.08.007_bb0175","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa2308900","article-title":"Simple versus radical hysterectomy in women with low-risk cervical cancer","volume":"390","author":"Plante","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"20","key":"10.1016\/j.ygyno.2025.08.007_bb0180","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1056\/NEJMoa1806395","article-title":"Minimally invasive versus abdominal radical hysterectomy for cervical cancer","volume":"379","author":"Ramirez","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"23","key":"10.1016\/j.ygyno.2025.08.007_bb0185","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1200\/JCO.23.02335","article-title":"LACC trial: final analysis on overall survival comparing open versus minimally invasive radical hysterectomy for early-stage cervical cancer","volume":"42","author":"Ramirez","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2025.08.007_bb0190","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.ygyno.2021.06.018","article-title":"Sentinel lymph node mapping in early-stage cervical cancer - a national prospective multicenter study (SENTIREC trial)","volume":"162","author":"Sponholtz","year":"2021","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2025.08.007_bb0195","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1006\/gyno.1999.5387","article-title":"A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: a Gynecologic Oncology Group Study","volume":"73","author":"Sedlis","year":"1999","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2025.08.007_bb0200","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ijrobp.2005.10.019","article-title":"A phase III randomized trial of postoperative pelvic irradiation in Stage IB cervical carcinoma with poor prognostic features: follow-up of a gynecologic oncology group study","volume":"65","author":"Rotman","year":"2006","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"8","key":"10.1016\/j.ygyno.2025.08.007_bb0205","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1200\/JCO.2000.18.8.1606","article-title":"Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix","volume":"18","author":"Peters","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2025.08.007_bb0210","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.5504","article-title":"Adjuvant chemotherapy following concurrent chemoradiation (CRT) in patients with high-risk early-stage cervical carcinoma following radical hysterectomy: results of NRG oncology\/RTOG 0724\/GOG-0724 (Abstract 5504)","volume":"42","author":"Jhingran","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.ygyno.2025.08.007_bb0215","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S1470-2045(23)00147-X","article-title":"Adjuvant chemotherapy following chemoradiotherapy as primary treatment for locally advanced cervical cancer versus chemoradiotherapy alone (OUTBACK): an international, open-label, randomised, phase 3 trial","volume":"24","author":"Mileshkin","year":"2023","journal-title":"Lancet Oncol."},{"issue":"10462","key":"10.1016\/j.ygyno.2025.08.007_bb0220","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/S0140-6736(24)01438-7","article-title":"Induction chemotherapy followed by standard chemoradiotherapy versus standard chemoradiotherapy alone in patients with locally advanced cervical cancer (GCIG INTERLACE): an international, multicentre, randomised phase 3 trial","volume":"404","author":"McCormack","year":"2024","journal-title":"Lancet"},{"issue":"10460","key":"10.1016\/j.ygyno.2025.08.007_bb0225","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/S0140-6736(24)01808-7","volume":"404","author":"Lorusso","year":"2024","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ygyno.2025.08.007_bb0230","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/cncr.27652","article-title":"The effect of treatment time in locally advanced cervical cancer in the era of concurrent chemoradiotherapy","volume":"119","author":"Song","year":"2013","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.ygyno.2025.08.007_bb0235","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.ijrobp.2019.10.042","article-title":"A phase II trial of stereotactic ablative radiation therapy as a boost for locally advanced cervical cancer","volume":"106","author":"Albuquerque","year":"2020","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"1","key":"10.1016\/j.ygyno.2025.08.007_bb0240","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.brachy.2016.09.011","article-title":"Differences in outcome for cervical cancer patients treated with or without brachytherapy","volume":"16","author":"Karlsson","year":"2017","journal-title":"Brachytherapy"},{"issue":"2","key":"10.1016\/j.ygyno.2025.08.007_bb0245","first-page":"121","article-title":"Survival and toxicity of radical radiotherapy (with or without brachytherapy) for FIGO stage I and II cervical cancer: a mono-institutional analysis","volume":"35","author":"Bandera","year":"2014","journal-title":"Eur. J. Gynaecol. Oncol."},{"key":"10.1016\/j.ygyno.2025.08.007_bb0250","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ygyno.2023.10.020","article-title":"Disparities in brachytherapy utilization in cervical cancer in the United States: a comprehensive literature review","volume":"179","author":"Kumar","year":"2023","journal-title":"Gynecol. Oncol."},{"issue":"8","key":"10.1016\/j.ygyno.2025.08.007_bb0255","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1056\/NEJMoa1309748","article-title":"Improved survival with bevacizumab in advanced cervical cancer","volume":"370","author":"Tewari","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"24","key":"10.1016\/j.ygyno.2025.08.007_bb0260","doi-asserted-by":"crossref","first-page":"5480","DOI":"10.1158\/1078-0432.CCR-15-1346","article-title":"Prospective validation of pooled prognostic factors in women with advanced cervical cancer treated with chemotherapy with\/without bevacizumab: NRG oncology\/GOG study","volume":"21","author":"Tewari","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"19","key":"10.1016\/j.ygyno.2025.08.007_bb0265","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1200\/JCO.2014.58.4391","article-title":"Paclitaxel plus carboplatin versus paclitaxel plus cisplatin in metastatic or recurrent cervical cancer: the open-label randomized phase III trial JCOG0505","volume":"33","author":"Kitagawa","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2025.08.007_bb0270","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.annonc.2024.10.002","article-title":"Pembrolizumab plus chemotherapy for advanced and recurrent cervical cancer: final analysis according to bevacizumab use in the randomized KEYNOTE-826 study","volume":"36","author":"Lorusso","year":"2025","journal-title":"Ann. Oncol."},{"issue":"10421","key":"10.1016\/j.ygyno.2025.08.007_bb0275","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(23)02405-4","article-title":"Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial","volume":"403","author":"Oaknin","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2025.08.007_bb0280","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.critrevonc.2016.11.006","article-title":"Management of patients with recurrent\/advanced cervical cancer beyond first line platinum regimens: where do we stand? A literature review","volume":"108","author":"Boussios","year":"2016","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"17","key":"10.1016\/j.ygyno.2025.08.007_bb0285","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1200\/JCO.18.01265","article-title":"Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase II KEYNOTE-158 study","volume":"37","author":"Chung","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.ygyno.2025.08.007_bb0290","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1056\/NEJMoa2112187","article-title":"Survival with Cemiplimab in recurrent cervical cancer","volume":"386","author":"Tewari","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.ygyno.2025.08.007_bb0295","doi-asserted-by":"crossref","first-page":"4125","DOI":"10.1007\/s12325-024-02975-x","article-title":"Efficacy of trastuzumab Deruxtecan in HER2-expressing solid tumors by enrollment HER2 IHC status: post hoc analysis of DESTINY-PanTumor02","volume":"41","author":"Oaknin","year":"2024","journal-title":"Adv. Ther."},{"issue":"1","key":"10.1016\/j.ygyno.2025.08.007_bb0300","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab Deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"18","key":"10.1016\/j.ygyno.2025.08.007_bb0305","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.1158\/1078-0432.CCR-23-0459","article-title":"FDA approval summary: Selpercatinib for the treatment of advanced RET fusion-positive solid tumors","volume":"29","author":"Duke","year":"2023","journal-title":"Clin. Cancer Res."},{"issue":"12","key":"10.1016\/j.ygyno.2025.08.007_bb0310","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41571-018-0113-0","article-title":"NTRK fusion-positive cancers and TRK inhibitor therapy","volume":"15","author":"Cocco","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.ygyno.2025.08.007_bb0315","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1001\/jamainternmed.2022.1022","article-title":"Hospital-administered cancer therapy prices for patients with private health insurance","volume":"182","author":"Xiao","year":"2022","journal-title":"JAMA Intern. Med."},{"issue":"12","key":"10.1016\/j.ygyno.2025.08.007_bb0320","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.46494","article-title":"Racial and ethnic disparities in clinical trial enrollment among women with gynecologic cancer","volume":"6","author":"Khadraoui","year":"2023","journal-title":"JAMA Netw. Open"},{"issue":"3","key":"10.1016\/j.ygyno.2025.08.007_bb0325","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1002\/cam4.5150","article-title":"Increasing patient participation in oncology clinical trials","volume":"12","author":"Chen","year":"2023","journal-title":"Cancer Med."},{"issue":"5","key":"10.1016\/j.ygyno.2025.08.007_bb0330","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1136\/ijgc-2022-003955","article-title":"Opioid and benzodiazepine use in gynecologic oncology patients","volume":"33","author":"Levytska","year":"2023","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"3","key":"10.1016\/j.ygyno.2025.08.007_bb0335","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.ygyno.2015.09.079","article-title":"Retrospective review of symptoms and palliative care interventions in women with advanced cervical cancer","volume":"139","author":"Kim","year":"2015","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2025.08.007_bb0340","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1200\/JCO.2016.70.1474","article-title":"Integration of palliative care into standard oncology care: American Society of Clinical Oncology clinical practice guideline update","volume":"35","author":"Ferrell","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2025.08.007_bb0345","doi-asserted-by":"crossref","first-page":"366","DOI":"10.4103\/jfmpc.jfmpc_1569_22","article-title":"Early integration of palliative care in cervical cancer: experiences from a pilot study","volume":"12","author":"Dey","year":"2023","journal-title":"J. Family Med. Prim. Care"},{"issue":"1","key":"10.1016\/j.ygyno.2025.08.007_bb0350","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1136\/ijgc-2020-001812","article-title":"Palliative care referral patterns and measures of aggressive care at the end of life in patients with cervical cancer","volume":"31","author":"Bercow","year":"2021","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"9","key":"10.1016\/j.ygyno.2025.08.007_bb0355","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1002\/ijc.34860","article-title":"Recent trends in cervical cancer incidence, stage at diagnosis, and mortality according to county-level income in the United States, 2000-2019","volume":"154","author":"Amboree","year":"2024","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ygyno.2025.08.007_bb2000","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ygyno.2025.07.029","article-title":"Health equity, disparities, and barriers to cervical cancer care in the U.S.: A consensus statement by SGO, ACOG, ASCCP, ASTRO, and ABS addressing the WHO cervical Cancer elimination campaign goals related to treatment","volume":"200","author":"Neibart","year":"2025","journal-title":"Gynecol. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825825009564?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825825009564?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T19:44:21Z","timestamp":1758915861000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825825009564"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":72,"alternative-id":["S0090825825009564"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2025.08.007","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Embracing and implementing the WHO cervical cancer elimination campaign goals: A consensus statement by SGO, ACOG, ASCCP, ASTRO, and ABS on minimum quality care standards for cervical cancer patients in the U.S","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2025.08.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}